Trastuzumab Emtansine / Ado-Trastuzumab Emtansine drug interactions | Litt's Drug Eruption and Reaction Database

Trastuzumab Emtansine / Ado-Trastuzumab Emtansine comment watch save

TRADE NAME: Kadcyla (Genentech)
INDICATIONS: HER2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination
SYNONYM: T-DM1
CLASS: Antibody-drug conjugate (ADC), Biologic, HER2-targeted antibody-drug conjugate, Monoclonal antibody
HALF-LIFE: 4 days

See adverse reactions attributed to class:
Antibody-drug conjugate (ADC)
Biologic
HER2-targeted antibody-drug conjugate
Monoclonal antibody

Formerly named Trastuzumab Emtansine.

HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

Page last updated 11/01/2024

Search drug eruptions and reactions data anytime, anywhere

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Hospitalization possible
Life threatening
Fatal

Breast feeding

Geriatric

Pediatric